Clonazolam


Clonazolam is a benzodiazepine that has had very little research done about its effects and metabolism, and has been sold online as a designer drug.
The synthesis of clonazolam was first reported in 1971 and the drug was described as the most active compound in the series tested.
Clonazolam is reported to be highly potent, and concerns have been raised that clonazolam and flubromazolam in particular may pose comparatively higher risks than other designer benzodiazepines, due to their ability to produce strong sedation and amnesia at oral doses of as little as 0.5 mg.

Legality

United Kingdom

In the UK, clonazolam has been classified as a Class C drug by the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.

United States

Virginia State Law has declared all of the following are now schedule I: clonazolam, etizolam, flualprazolam, flubromazolam, and flubromazepam.

Sweden

Sweden's public health agency suggested classifying clonazolam as a hazardous substance on June 1, 2015.

Effects

Clonazolam's effects are similar to other benzodiazepines, such as anxiolysis, disinhibition, lethargy, muscle relaxation, and euphoria. While no dose of clonazolam is considered "safe" due to its lack of research and extreme potency, doses higher than 0.5 mg can cause benzodiazepine overdose in some individuals. The effects of a benzodiazepine overdose include sedation, confusion, insufficient breathing, loss of consciousness, and death. Because dependence can occur in a short period of time, or even with a large initial dose, withdrawal symptoms may occur acutely, following the period of intoxication. These include seizures and can result in death.